Pharmacy payments in the oregon workers' compensation system, first quarter 2004
Pharmacy Payments in the Oregon
Workers’ Compensation System,
First Quarter 2004
Department of Consumer & Business Services
The estimated medical payments for treating injured workers during the fi rst calendar quarter of 2004 totaled $66,215,300. This represents a 12 percent increase from the estimated $59,090,500 in total medical payments re-ported during the fi rst calendar quarter of 2002.1 Estimated pharmacy payments totaled $4,106,900 (6.2 percent of total medical payments), up from $3,604,500 (6.1%) in the fi rst quarter of 2002.
Figure 1 breaks down pharmacy payments by drug class (also known as drug category). A drug class contains drugs with similar actions and uses. Narcotic analgesics continue to rank fi rst among the drug classes dispensed to in-jured workers, receiving more than one-third of pharmacy payments. Narcotic analgesic payments are followed by anti-arthritics (also known as anti-infl ammatories) and anti-convulsants (anti-seizure medications), at 16.7 and 11.2 percent of total pharmacy payments, respectively.2
On the following page, Table 1 shows the top pharmacy payments by drug name and pharmacy payments. In 2004, oxycodone HCL, a narcotic analgesic (pain reliever) continued to receive the highest aggregate payment, repre-senting 15.9 percent of pharmacy payments. The top 25 drugs, as a whole, represented nearly 70 percent of phar-macy payments.
Further analysis of workers’ compensation
Figure 1. Top drug classes by pharmacy
pharmacy data shows a higher use of generic
payments, first quarter 2004
drugs than in general health care. In 2004, generic drugs represented 56 percent of dis-
pensed prescriptions in general health care,
representing 17 percent of the total dollars
spent on dispensed prescriptions.3 In Oregon’s
workers’ compensation system, generic drugs
scriptions and 26 percent of the total dollars
spent on prescriptions in the fi rst quarter
of 2004, compared with 62 percent and 26
percent, respectively, in the fi rst quarter of 2002. Additionally, when generic and brand
name versions of a drug within the top fi ve drug classes are both available, the generic is
dispensed more than 90 percent of the time.
Because the top fi ve drug classes contribute
over four-fi fths of the total dollars, the work-
ers’ compensation system has experienced signifi cant cost savings as a result of generic
Note: Percents may not total 100 due to rounding.
2 It is common for anti-convulsants, most often Neurontin, to be prescribed for purposes other than seizure suppression; typically for “off-label”
use in relieving neuropathic and neurogenic pain and in migraine prophylaxis. The FDA approves a drug for a specifi c, labeled purpose, but some drug references, such as the Physicians’ Desktop Reference
, provide alternative, “off-label” purposes.
3 See IMS Health, a pharmaceutical information and consulting company, National Prescription Audit Plus™ and National Sales Perspectives™,
Table 1. Top 25 drug names by pharmacy payment
Norco, Lortab, Vicodin (ES and HP), Lorcet
Remaining pharmacy payments
Note: Drug payment fi gures are rounded to the nearest hundred; fi gures and percents may not add to totals due to rounding.
If you have questions about the information contained in this document, please contact by ch Analyst, (503) 947-7194, Research & Analysis Section, Information Management Division.
In compliance with the Americans with Disabilities Act (ADA), this publication
is available in alternative formats. Please call (503) 378-4100 (V/TTY).
The information in this report is in the public domain and may be reprinted
without permission. Visit the DCBS Web site
To receive electronic notifi cation of new publications, see the Information Management WebBoard,
PLEASE BE CERTAIN THAT YOU RESPOND ACCURATELY TO ALL THE QUESTIONS. FAILURE TO DO SO WILL JEOPARDISE YOUR LICENCE AGREEMENT (SHOULD YOU BE OFFERED ACCOMMODATION AT ST ED’S). BY SIGNING BELOW YOU ARE STATING THAT YOU UNDERSTAND & ACCEPT THE ABOVE CONDITION. Please sign………………………. ST EDMUNDS CHARITY RESETTLEMENT PROJECT ASSESSMENT FORM July
Development Policy Review, 2007, 25 (3): xx-xx Commercialisation of Non-Timber Forest Products: A Reality Check Brian Belcher and Kathrin Schreckenberg∗ This article challenges the pervasive view that commercialisation of non-timber forest products can (easily) achieve ecosystem and species conservation as well as improving livelihoods. Following a brief review of who and what is involved, i